Biogen CEO Pursues Collaborations to Boost R&D Amid Drug Launches and Profit Forecast Cuts
TL;DR Summary
Biogen CEO Chris Viehbacher announced plans for more collaborations to expand the company's early-stage R&D work, following its recent acquisition of Reata Pharmaceuticals. While reporting strong third-quarter revenues, Viehbacher acknowledged that investors are more concerned about Biogen's future growth prospects. He ruled out any major acquisitions in the near term but emphasized the company's focus on partnerships to fill out its pipeline.
- Biogen CEO seeks 'awful lot more collaborations' to beef up R&D as it launches postpartum depression, Alzheimer's and ALS drugs Endpoints News
- Biogen Skids On 'Low-Quality' Beat, Profit Guidance Haircut Investor's Business Daily
- Biogen cuts profit forecast on Alzheimer's drug launch, deal costs Yahoo Finance
- As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches FiercePharma
- Biogen Lowers 2023 Earnings Guidance on Costs of Reata Purchase Bloomberg
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
60%
155 → 62 words
Want the full story? Read the original article
Read on Endpoints News